The Spectranetics Corp

The Spectranetics — Spectranetics — Technical Presentation (November 2016)

20 slides from The Spectranetics's technical presentation, Nov 2, 2016

  1. Slide 1: ILLUMENATE Pivotal Stellarex DCB IDE Study 12-Month Results

    ILLUMENATE Pivotal Stellarex DCB IDE Study 12-Month Results Sean Lyden, MD On behalf of Co-PI Prakash Krishnan, MD and the ILLUMENATE Pivotal Investigators Cleveland Clinic Cleveland, Ohio

  2. Slide 2: Disclosure Statement of Financial Interest

    Disclosure Statement of Financial Interest • Grant/Research Support • Consulting Fees/Honoraria • Other Financial Benefit • Cook, Cordis, Gore, Endologix, Bolton, Silkroad, Trivascular, Medtronic, Spectranetics, Bard • Spectranetics, Biomet, Endologix, TVA Medical • VIVA Physicians Board Member With

  3. Slide 3: Background

    Background  SFA disease remains a challenge to manage  Current PTA results from DCB trials are associated with improved outcomes over OPC goals 1,2,3  Drug-coated balloons have improved patency over PTA in randomized trials 1,2  Severe calcium, diabetes, CKD, women and small vessels remain a pro

  4. Slide 4: Study Device: Stellarex DCB

    Study Device: StellarexTM DCB (Spectranetics) CAUTION: Investigational device. Not for sale or distribution in the United States. EnduraCoatTM technology: • Low dose paclitaxel, 2 µg/mm2 • Excipient: Polyethylene Glycol (PEG) • Proprietary open-folded coating technology Balloon catheter features: •

  5. Slide 5: Stellarex Program: Sites & Investigators

    Stellarex Program: Sites & Investigators ILLUMENATE FIH 80 subjects enrolled 3 EU sites ILLUMENATE Pivotal IDE 300 subjects enrolled 43 US & EU sites ILLUMENATE Global 371 subjects enrolled 37 EU & AUS/NZ sites ILLUMENATE EU RCT 328 subjects enrolled 18 EU sites ILLUMENATE PK 25 subjects enrolled 2

  6. Slide 6: Trial Objective and Design

    Trial Objective and Design • Stellarex DCB vs. PTA • Multicenter prospective randomized trial • Follow-up for 5 years • Independent adjudication: • Angiographic Core Laboratory1 • Duplex Ultrasound Core Laboratory2 • Clinical Events Committee • Data Safety Monitoring Board • Monitoring with 100% sou

  7. Slide 7: Primary Endpoints

    Primary Endpoints Primary Safety Endpoint: Freedom from device- and procedure-related death through 30 days and freedom from target limb major amputation and clinically-driven TLR through 12 months Primary Effectiveness Endpoint: Primary patency at 12 months, defined as freedom from target lesion re

  8. Slide 8: Key Eligibility Criteria

    Key Eligibility Criteria Key Inclusion Criteria • Rutherford class 2, 3 or 4 • Lesion located in the SFA and/or popliteal • Has at least one patent run-off vessel below-the-knee • Lesion length 3-18 cm Key Exclusion Criteria • Acute or sub-acute thrombus in target vessel • Significant inflow disease

  9. Slide 9: Baseline Characteristics

    Baseline Characteristics ITT Data Set Stellarex PTA p Age (years) 68.3 ± 10.3 (200) 69.8 ± 9.8 (100) 0.225 Rutherford Clinical Category 0.735 2 31.5% (63/200) 35.0% (35/100) 3 64.5% (129/200) 60.0% (60/100) 4 4.0% (8/200) 5.0% (5/100) ABI 0.75±0.21 (193) 0.76± 0.2 (100) 0.508 Hypertension 93.5% (187

  10. Slide 10: Baseline Characteristics

    Baseline Characteristics ITT Data Set Stellarex PTA p Female 44% (88/200) 36% (36/100) 0.185 Diabetes 49.5% (99/200) 52.0% (52/100) 0.683 Renal Insufficiency 18.0% (36/200) 16.0% (16/100) 0.666 BMI ≥ 30 39.5% ( 79 /200) 30.0% (30/100) 0.107 Previous or Current Smoker 84.0% (168/200) 75.0% (75/100) 0

  11. Slide 11: Baseline Core Lab Angiographic Data

    Baseline Core Lab Angiographic Data ITT Data Set Stellarex PTA p Lesion Length (cm) 8.0 ± 4.5 (199) 8.9 ± 4.6 (100) 0.105 Restenotic1 9.5% (19/200) 18.0% (18/100) 0.035 Total Occlusion 19.0% (38/200) 18.0% (18/100) 0.834 Severe Calcification 43.9% (87/198) 43.0% (43/100) 0.877 Diameter Stenosis (%)

  12. Slide 12: Procedural Characteristics

    Procedural Characteristics Stellarex PTA p Pre-dilatation Performed1 100% (200/200) 100% (100/100) N/A Study Device Inflation Time1 (min/lesion) 3.9 ± 2.0 (200) 3.7 ± 2.3 (100) 0.557 Post-DCB/PTA Dissection2 Grade D Grade E/F (Flow-limiting) 20.0% (40/200) 0.0% (0/193) 12.0% (12/100) 0.0% (0/98) 0.0

  13. Slide 13: Primary Safety Endpoint

    Primary Safety Endpoint ITT Data Set Composite of freedom from device & procedure-related death through 30 days post-procedure and freedom from target limb major amputation and CD-TLR through 12 months post-procedure (410 days) • Stellarex1: 92.1% (174/189) • PTA1: 83.2% (79/95) • Difference: [95%CI

  14. Slide 14: Key Safety Outcomes

    Key Safety Outcomes ITT Data Set Stellarex PTA Difference [95% CI]2 12-Month MAEs1 9.4% (18/191) [18] 17.7% (17/96) [18] -8.3% [-17.0%, 0.4%] CV Death 1.6% (3/191) [3] 2.1% (2/96) [2] -0.5% [-3.9%, 2.8%] Target Limb Amputation 0.0% (0/189) [0] 0.0% (0/95) [0] N/A Clinically- Driven TLR 7.9% (15/189)

  15. Slide 15: CD-TLR Free at 12 Months

    CD-TLR1 Free at 12 Months: 93.6% ITT Data Set 1. Clinically-driven TLR defined as reintervention due to PSVR≥2.5 (or >50% stenosis via angio) with an increase in the RCC >1 category or deterioration in the ABI by >0.15 compared to maximum early post-procedural level. Per subject analysis. 80.0% @ da

  16. Slide 16: Primary Effectiveness Endpoint

    12 Month Primary Effectiveness Endpoint ITT Data Set Absence of restenosis (Duplex PSVR ≤ 2.5) & freedom from CD-TLR through 12 months (410 days) • Stellarex1: 76.3% (135/177) • PTA1: 57.6% (53/92) • Difference: [95% CI]2 16.9% [5.1%, 28.7%] • P=0.003 Superiority Endpoint Achieved 1 Data are based o

  17. Slide 17: Key Secondary Endpoints

    Key Secondary Endpoints ITT Data Set Percent of Subjects with Improvements at 12 Months vs. Baseline 1. CD-TLR rate in the Stellarex arm = 7.9% vs. 16.8% in the PTA arm 73.8% 86.9% 79.0% 73.0% 88.3% 75.8% Walking Distance (6 MWT) RCC Classification Ankle-Brachial Index PTA Stellarex Similar outcomes

  18. Slide 18: Primary Patency at 12 Months

    Primary Patency at 12 Months ITT Data Set Primary patency is defined as freedom from restenosis (determined by duplex ultrasound PSVR threshold of 2.5) and freedom from clinically-driven TLR at 12 months. Assessed per lesion. KM estimates reported at day 410 to capture all patients and events within

  19. Slide 19: Data in Context with Core Lab Adjudicated 12-Month Patency Rates

    Data in Context with Core Lab* Adjudicated 12-Month Patency Rates 1. Brodmann M. Oral presentation. AMP Symposium, Chicago, IL, Aug 10, 2016 2. Laird JR et al. J Am Coll Cardiol 2015;66:2329-38, P.Krishnan Oral Presentation. VIVA 2016 3. Rosenfield K, Jaff MR, White CJ, et al. The New England Journa

  20. Slide 20: Conclusions

    Conclusions • Stellarex is a low-dose (2 µg/mm2) DCB • One of the most complex patient groups studied in DCB IDE trials • Severe calcium 43.9%, diabetes 49.5%, 0-1 runoff 32.5% • 12-Month DCB Primary Patency: 82.3% • 12-Month DCB Freedom from CD-TLR: 93.6% • Both primary safety and effectiveness end

Spectranetics — Technical Presentation (November 2016) on 6ix